STERIS Q1 FY2027: Revenue +7.3%, EPS $2.04; New $1B Buyback; $55M-$70M Restructuring Announced
STE sits 22% above its 52-week low of $195.14.
Summary
STERIS reported Q1 FY2027 revenue of $1.49B (+7.3%) and diluted EPS of $2.04 (+14%), authorized a new $1B buyback, and announced a $55M-$70M restructuring plan.
Key Events · Earnings and Guidance · STE
-
Q1 Revenue +7.3%, EPS $2.04
Revenue reached $1,492.7M, up 7.3% YoY, with Healthcare +7.6%, AST +5.8%, and Life Sciences +8.6%. Diluted EPS rose 14% to $2.04, driven by volume and pricing.
-
New $1B Share Repurchase Program
The board terminated the prior $500M program and authorized a new $1.0B buyback. $100M was repurchased in Q1, leaving $900M remaining.
-
Subsequent Restructuring Announced
On August 5, 2026, STERIS announced a plan to consolidate chemistries manufacturing, expecting $55M-$70M in pre-tax charges through fiscal 2030, with $40M-$50M in cash costs.
-
Tax Rate Headwind
The effective tax rate increased to 26.5% from 23.3% due to unfavorable discrete items, partially offsetting operating income growth.
Analysis · STE · Industrial Applications And Services
A solid start to fiscal 2027 saw STERIS deliver 7.3% revenue growth and a 14% advance in EPS, fueled by volume and pricing gains across all segments. The board replaced the prior $500 million plan with a new $1.0 billion share repurchase authorization and bought back $100 million in shares during the quarter. After quarter-end, the company announced a $55M-$70M restructuring to consolidate chemistries manufacturing, aiming to improve efficiency over the next several years. The effective tax rate rose to 26.5%, pressuring net income growth relative to pre-tax income. Free cash flow declined year-over-year due to working capital changes, but the balance sheet remains strong with debt-to-capital of 20.9%.
At the time of this filing, STE was trading at $237.47 on NYSE in the Industrial Applications And Services sector, with a market capitalization of approximately $23.1B. The 52-week trading range was $195.14 to $269.44. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.